Multicenter Prevention Trial of Slowly Progressive Type 1 Diabetes with Small Dose of Insulin (the Tokyo Study): Preliminary Report
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A bstract: In 1996, we designed a randomized multicenter study to assess the effects of small doses of insulin on beta cell failure in slowly progressive type 1 diabetes (the Tokyo Study). We report here the preliminary results of this study. Glutamic acid decarboxylase 65 antibody (GADA)‐positive patients were randomly divided into 2 groups: one group received insulin (Ins group), the other a sulfonylurea (SU group). Fifty‐four patients (24 Ins group, 30 SU group) were analyzed at the end of a 4‐year period. All patients underwent a 75 g oral‐glucose test (O‐GTT) every 6‐12 months. The insulin‐dependent stage was defined based on an integrated value of serum C‐peptide levels on O‐GTT (∑CPR; sum of CPR at 0, 30, 60, 90, and 120 min) below 4.0 ng/mL. The ∑CPR in the SU group decreased progressively from 22.0 ± 10.6 to 11.3 ± 7.5 ng/mL over the 48‐month period (p < 0.001 vs. baseline). The ∑CPR in the Ins group was unchanged. Among the SU group, 30% of subjects (9/30) progressed to IDDM, while 8.3% of Ins group subjects (2/24) progressed to IDDM (p= 0.087). With regard to the subjects who had a preserved C‐peptide response (∑CPR ≥ 10 ng/mL), the proportion of SU group subjects who progressed to IDDM was significantly higher than that of the Ins group (7/28, 25% vs. 0/21, 0%, p= 0.015). Among subjects with a high GADA titer (≥0 U/mL), 9/14 (64.3%) of the SU group, but only 2/16 (12.5%) of the Ins group, developed IDDM (p= 0.0068). As to those with a high GADA titer and a preserved C‐peptide response, SU group subjects progressed to IDDM (7/12, 58.3%) more frequently than Ins group subjects (0/14, 0%) (p= 0.0012). In summary, our results suggest that small doses of insulin effectively prevent beta cell failure in slowly progressive type 1 diabetes. We recommend avoiding SU treatment and instead administering insulin to NIDDM patients with high GADA titer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Cited by
Latent autoimmune diabetes in adults (LADA) should be less latent
Fourlanos, S., Dotta, F., Greenbaum, C. J., Palmer, J. P., Rolandsson, O., Colman, P. G., & Harrison, L. C. (2005) · Diabetologia · doi:10.1007/s00125-005-1960-7 · Cited by 401
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020) · Diabetes · doi:10.2337/dbi20-0017 · Cited by 305
Adult-onset autoimmune diabetes: current knowledge and implications for management
Buzzetti, R., Zampetti, S., & Maddaloni, E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.99 · Cited by 271
“Furthermore, a new autoantibody against the extracytoplasmatic (EC) IA-2EC(26-577) region can identify a novel antigenic determinant within the N terminus of the IA-2 protein76.”
BackgroundType 1 Diabetes and Latent Autoimmune Diabetes in Adults: One End of the Rainbow
Leslie, R. D. G., Williams, R., & Pozzilli, P. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1623 · Cited by 142
Metadata
- Authors
- MARUYAMA, T., SHIMADA, A., KANATSUKA, A., KASUGA, A., TAKEI, I., YOKOYAMA, J., & KOBAYASHI, T.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2003-11
- Volume
- 1005
- Issue
- 1
- Pages
- 362-369
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1992251328
- Cited by
- 46
- References
- 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.